Nefropatía tubulointersticial grave secundaria a 5-ASA

Bosque López, M. José; Garrido Durán, Carmen; Ginard Vicens, Daniel; Munar Vila, M. Antonia; Vanrell Garau, Margalida; Mariño Méndez, Zoe; Gayà Cantallops, Jaime.
Gastroenterol. hepatol. (Ed. impr.) ; 32(1): 29-31, ene. 2009. graf
Artículo en Español | IBECS (España) | ID: ibc-61365

Documentos relacionados

  1. Risk factors for intolerance of oral 5-aminosalicylic acid preparations in pediatric ulcerative colitis.
  2. Serum Bile Acid Metabolites Predict the Therapeutic Effect of Mesalazine in Patients with Ulcerative Colitis.
  3. The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis.
  4. Antibiotics for the induction and maintenance of remission in ulcerative colitis.
  5. Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis.
  6. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
  7. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial.
  8. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition.
  9. The culprit of mesalamine intolerance: case series and literature review.
  10. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.